StatOrigin open statistical archive
Live Industries Statistics Regions Rankings Reports Compare Sources

C21 · Pharmaceuticals · 3 regions

Radioligand therapy trial starts

Global: 79 in 2025, +0.0% on 2024.

  • 79 Latest · Global · 2025
  • +0.0% vs 2024
  • Annual Release cadence
  • 21 Records · 3 regions · 2020–2026

Verified 27 Sep 2026 · 1 publisher · Next period 2026

CSV Excel JSON PNG Cite and reuse

Across regions

3 regions on one axis, spaced by time. Below it, selected latest values by region. Forecasts are dashed with hollow markers; the underlying values are one click away under the chart.

Fig 1 · C21 · 3 regions Annual

Radioligand therapy trial starts by region

3 regions, 2020 to 2025

3 regions · 18 observations · 2020 to 2025
Radioligand therapy trial starts by regionRadioligand therapy trial starts by region. 3 regions on one axis: Global, United States, China. 18 observations from 2020 to 2025, ranging from 2 to 291. Latest values: Global 79 (2025); United States 39 (2025); China 22 (2025). 0 100 200 300 2020 2021 2022 2023 2024 2025 Global United States China
Radioligand therapy trial starts by regionRadioligand therapy trial starts by region. 3 regions on one axis: Global, United States, China. 18 observations from 2020 to 2025, ranging from 2 to 291. Latest values: Global 79 (2025); United States 39 (2025); China 22 (2025). 0 100 200 300 2020 2021 2022 2023 2024 2025 Global United States China
Radioligand therapy trial starts by regionRadioligand therapy trial starts by region. 3 regions on one axis: Global, United States, China. 18 observations from 2020 to 2025, ranging from 2 to 291. Latest values: Global 79 (2025); United States 39 (2025); China 22 (2025). 0 100 200 300 2020 2021 2022 2023 2024 2025 Global United States China
View the underlying data
Radioligand therapy trial starts by region
Region Period Type Value
Global 2025 Actual 79
Global 2024 Actual 79
Global 1 Jan 2023 to 27 Sep 2026 Actual 291
Global 2022 Actual 50
Global 2021 Actual 31
Global 2020 Actual 36
United States 2025 Actual 39
United States 2024 Actual 37
United States 1 Jan 2023 to 27 Sep 2026 Actual 127
United States 2022 Actual 27
United States 2021 Actual 15
United States 2020 Actual 17
China 2025 Actual 22
China 2024 Actual 19
China 2023 Actual 18
China 2022 Actual 9
China 2021 Actual 6
China 2020 Actual 2
Source: ClinicalTrials.gov · CC BY 4.0 · statorigin.org
Fig 2 · C21 · Latest by region

Radioligand therapy trial starts by region

Latest value per region, 2025

3 entries
Radioligand therapy trial starts by regionRadioligand therapy trial starts by region. 3 categories, highest is Global at 79. China United States Global 22 39 79
Radioligand therapy trial starts by regionRadioligand therapy trial starts by region. 3 categories, highest is Global at 79. China United States Global 22 39 79
Radioligand therapy trial starts by regionRadioligand therapy trial starts by region. 3 categories, highest is Global at 79. China United States Global 22 39 79
View the underlying data
Radioligand therapy trial starts by region
Category Source Type Value
Global ClinicalTrials.gov Actual 79
United States ClinicalTrials.gov Actual 39
China ClinicalTrials.gov Actual 22
Source: ClinicalTrials.gov · CC BY 4.0 · statorigin.org

Every record

21 records · 3 regions · 2020–2026. Each period links to its record: the value, its source evidence and original document.

Radioligand therapy trial starts: every record, grouped by region, newest first.
Period Value Source Type
Global 7 records
2025 79 ClinicalTrials.gov · 31 Dec 2025
2024 79 ClinicalTrials.gov · 31 Dec 2024
1 Jan 2023 to 27 Sep 2026 291 ClinicalTrials.gov · 27 Sep 2026
2023 67 ClinicalTrials.gov · 31 Dec 2023
2022 50 ClinicalTrials.gov · 31 Dec 2022
2021 31 ClinicalTrials.gov · 31 Dec 2021
2020 36 ClinicalTrials.gov · 31 Dec 2020
United States 7 records
2025 39 ClinicalTrials.gov · 31 Dec 2025
2024 37 ClinicalTrials.gov · 31 Dec 2024
1 Jan 2023 to 27 Sep 2026 127 ClinicalTrials.gov · 27 Sep 2026
2023 24 ClinicalTrials.gov · 31 Dec 2023
2022 27 ClinicalTrials.gov · 31 Dec 2022
2021 15 ClinicalTrials.gov · 31 Dec 2021
2020 17 ClinicalTrials.gov · 31 Dec 2020
China 7 records
2025 22 ClinicalTrials.gov · 31 Dec 2025
2024 19 ClinicalTrials.gov · 31 Dec 2024
1 Jan 2023 to 27 Sep 2026 75 ClinicalTrials.gov · 27 Sep 2026
2023 18 ClinicalTrials.gov · 31 Dec 2023
2022 9 ClinicalTrials.gov · 31 Dec 2022
2021 6 ClinicalTrials.gov · 31 Dec 2021
2020 2 ClinicalTrials.gov · 31 Dec 2020

Download this data

PNG chart SVG chart CSV data Excel data JSON series API

Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: ClinicalTrials.gov. Licence: CC BY 4.0.

Embed this chart

For automatic sizing and multiple charts, see the JavaScript embed guide.

Free to embed anywhere, including commercially. The attribution bar is part of the chart. The link under the frame is optional: keep it, remove it or mark it rel="nofollow".

<iframe src="https://statorigin.org/embed/pharmaceuticals--ctgov-rlt-trial-starts--regions" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Radioligand therapy trial starts by region" loading="lazy"></iframe>
<p><a href="https://statorigin.org/indicators/ctgov-rlt-trial-starts">Data: ClinicalTrials.gov via StatOrigin</a> · CC BY 4.0</p>
Preview embed

Use and publication rights

  • View, cite and link: free

    Quote any number, cite this page or a single record, and link to it anywhere.

  • Copy, chart and republish: free with attribution

    The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (ClinicalTrials.gov); the chart files already carry that line.

  • The source documents: the publisher's terms

    Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.

How this measure is built

Definition
Count of interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
Measure
One slice of Clinical trial starts ( basis: clinicaltrials gov registry, counting rule: by start date, form: count, segment: rlt ) . Total number of clinical trials initiated during a given period. Region and period are columns on every record, not slices.
Limitations
Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
Verification
Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.

Sources · 21 documents

Document Publisher Published Data points
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1

Other slices of clinical trial starts

Frequently asked questions

What is the latest radioligand therapy trial starts?

Global: 79 in 2025, +0.0% on 2024.

Where does this data come from?

From 21 documents published by ClinicalTrials.gov. Every figure on this page links to its record, which preserves the original source evidence.

How often is it updated?

Annual. The newest published period is 2025; the next release should cover 2026. A new figure appears here once the publisher releases it and it passes verification.

Can I use this data?

Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.

Cite this page

Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.

StatOrigin. (2026). Radioligand therapy trial starts [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/ctgov-rlt-trial-starts

"Radioligand therapy trial starts." StatOrigin, 2026, https://statorigin.org/indicators/ctgov-rlt-trial-starts. Accessed 28 Oct. 2026.

StatOrigin. "Radioligand therapy trial starts." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/ctgov-rlt-trial-starts.

@misc{statorigin_ctgov_rlt_trial_starts_2026, title = {Radioligand therapy trial starts}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/ctgov-rlt-trial-starts}, note = {Data set. Accessed 2026-10-28} }